drugset / Trial / NCT04456803

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

NCT04456803

Phase 3 Completed 239 enrolled Sinomune Pharmaceutical Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of ferric citrate tablet in the control of serum phosphorus levels in patients with chronic kidney disease undergoing hemodialysis.

Timeline

Start
2019-05-24
Primary completion
2022-09-13
Completion
2022-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric Citrate Unknown 250 mg
Comparator sevelamer Other / unclassified 800 mg